Recent clinical advances in lung cancer management

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 973-982

  Johnson, David H ^a   Schiller, Joan H ^a   Bunn Jr , Paul A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IPILIMUMAB; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZOLEDRONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERDISCIPLINARY RESEARCH; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEDICAL HISTORY; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION; EARLY DIAGNOSIS; GENETICS; LUNG TUMOR; PATHOLOGY; PROTO ONCOGENE;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA;

EID: 84901604030     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1228     Document Type: Review

References (125)

1. Travis W, Brambilla E, Muller-Hermelink H, et al (eds): Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France, IARC Press, 2004
2. Horn L, Pao W, Johnson DH: Neoplasms of the lung, in Fauci AS, Braunwald E, Kasper DL, et al (eds): Harrison's Principles of Internal Medicine (ed 18). New York, NY, McGraw-Hill, 2010
3. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006 (Pubitemid 46630948)
4. Chen F, Cole P, Bina WF: Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 16:2724-2729, 2007 (Pubitemid 351210549)
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
6. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
7. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
8. Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guidelines for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer and Association for Moleclar Pathology. J Thorac Oncol 8:823-859, 2013
9. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
10. Socinski M, Smit EF, Lorigan P, et al: Phase III study of pemetrexed plus carboplatin compared to etoposide plus carboplatin in chemotherapy-naïve patients with extensive stage small-cell lung cancer. J Clin Oncol 27:4787-4792, 2009
11. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
12. Travis WD, Brambilla E, Riely GJ: New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 3:992-1001, 2013
13. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
14. Warth A, Muley T, Meister M, et al: The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438-1446, 2012
15. Kris MG, Johnson B, Berry L, et al: Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: Results from the Lung Cancer Mutation Consortium (LCMC). International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer, Sydney, Australia, October 27-31, 2013 (abstr PL03.07)
16. Cardarella S, Ogino A, Nishino M, et al: Clinical, pathologic and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532-4540, 2013
17. Mazieres J, Peters S, Lepage B, et al: Lung cancer that harbors a Her2 mutation: Epidemiologic charactestics and therapeutic perspectives. J Clin Oncol 31:1997-2003, 2013
18. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
19. Davies KD, Le AT, Theodoro MF, et al: Identifying and targeting ROS 1 fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579, 2012
20. Wang R, Hu H, Pan Y, et al: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30:4352-4359, 2012
21. Cancer Genomic Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
22. Rudin CM, Durinck S, Stawiski EW, et al: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44:1111-1116, 2012
23. Peifer M, Fernández-Cuesta L, Sos ML, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104-1110, 2012
24. Patz EF Jr, Goodman PC, Bepler G: Screening for lung cancer. N Engl J Med 343:1627-1633, 2000 (Pubitemid 32162988)
25. Dominioni L, Strauss GM, Imperatori A, et al: Screening for lung cancer. Chest Surg Clin North Am 10:729-736, 2000
26. Oken MM, Hocking WG, Kvale PA, et al: Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306:1865-1873, 2011
27. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409, 2011
28. Henschke CI, McCauley DI, Yankelevitz DF, et al: Early Lung Cancer Action Project: Overall design and findings from baseline screening. Lancet 354:99-105, 1999 (Pubitemid 29313143)
29. Henschke CI, Yankelevitz DF, Libby DM, et al: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355:1763-1771, 2006 (Pubitemid 44631359)
30. Boiselle PM: Computed tomography screening for lung cancer. JAMA 309:1163-1170, 2013
31. Bach PB, Mirkin JN, Oliver TK, et al: Benefits and harms of CT screening for lung cancer: A systematic review. JAMA 307:2418-2429, 2012
32. Reference deleted
33. Reference deleted
34. Ettinger DS, Akerly W, Borghaei H, et al: Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11:645-653, 2013
35. Lam S, McWilliams A, Mayo J, et al: Computed tomography screening for lung cancer: What is a positive screen? Ann Intern Med 158:289-290, 2013
36. Tammemägi MC, Katki HA, Hocking WG, et al: Selection criteria for lung-cancer screening. N Engl J Med 368:728-736, 2013
37. Woloshin S, Schwartz LM, Black WC, et al: Cancer screening campaigns: getting past uninformative persuasion. N Engl J Med 367:1677-1679, 2012
38. van der Aalst CM, van Klaveren RJ, van den Bergh KA, et al: The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J 37:1466-1473, 2011
39. Vallières E, Shepherd FA, Crowley J, et al: The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4:1049-1059, 2009
40. Bunn PA Jr, Lichter AS, Makuch RW, et al: Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: A prospective, randomized trial. Ann Intern Med 106:655-662, 1987 (Pubitemid 17067980)
41. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992
42. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999 (Pubitemid 29063268)
43. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993 (Pubitemid 23046826)
44. Bunn PA Jr, Crowley J, Kelly K, et al: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13:1632-1641, 1995
45. Kalemkerian GP, Akerly W, Bogner P, et al: Small cell lung cancer. J Natl Compr Canc Netw 11:78-98, 2013
46. Samson DJ, Seidenfeld J, Simon GR, et al: Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:314S-323S, 2007 (Pubitemid 47502816)
47. Arriagada R, Le Chevalier T, Borie F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer incomplete remission. J Natl Cancer Inst 87:183-190, 1995
48. Slotman BJ, Mauer ME, Bottomley A, et al: Prophylactic cranial irradiation in extensive disease small-cell lung cancer: Short-term health-related quality of life and patient reported symptoms-Results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol 278:78-84, 2009
49. Le Péchoux C, Laplanche A, Faivre-Finn C, et al: Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 22:1154-1163.49, 2011
50. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
51. Murray N, Livingston RB, Shepherd FA, et al: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17:2300-2308, 1999 (Pubitemid 29368227)
52. Ardizzoni A, Hansen H, Dombernowskt P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease - The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997
53. Eckhardt JR, von Pawel J, Pujol JL, et al: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086-2092, 2007
54. O'Brien ME, Cuileanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441-5447, 2006 (Pubitemid 46623178)
55. Reference deleted
56. Batist G, Ihde DC, Zabell A, et al: Small-cell carcinoma of lung: Reinduction therapy after late relapse. Ann Intern Med 98:472-474, 1983 (Pubitemid 13116615)
57. Reference deleted
58. Reck M, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:75-83, 2013
59. Mountain CF, McMurtrey MJ, Frazier BH, et al: Recent status of postoperative adjuvant therapy for lung cancer. Cancer Bull 32:1008-1112, 1980
60. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995
61. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008
62. Arriagada R, Auperin A, Burdett S, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet 375:1267-1277, 2010
63. Pisters KM, Valières E, Crowley JJ, et al: Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28:1843-1849, 2010
64. Felip E, Rosell R, Maestre JA, et al: Preoperative chemothereapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 28:3138-3145, 2010
65. Song WA, Zhou NK, Wang W, et al: Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: An updated meta-analysis of 13 randomized controlled trials. J Thorac Oncol 5:510-516, 2010
66. Strauss GM, Herndon JE 2nd, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Study Groups. J Clin Oncol 26:5043-5051, 2008
67. Kratz JR, He J, Van Den Eeden SK, et al: A practical molecular assay to predict survival in resected non-squamous, non-small cell lung cancer: Development and international validation studies. Lancet 379:823-832, 2012
68. Zhu CQ, Ding K, Strumpf D, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28:4417-4424, 2010
69. PORT Meta-Analysis Trialists Group: Postoperative radiotherapy in non-small cell lung cancer, systemic review and meta-analysis of indirected patient data from nine randomized controlled trials. Lancet 352:1384-1385, 1996
70. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in Stage III non-small cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996 (Pubitemid 26302034)
71. Curran WJ, Paulus R, Langer CJ, et al: Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460, 2011
72. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999 (Pubitemid 29415225)
73. Albain KS, Swann RS, Rusch VW, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 374:379-386, 2009
74. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891, 2005
75. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755-5760, 2008
76. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomzied study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced NSCLC: Results of an European Multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
77. Rapp E, Pater JL, Wilan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
78. Reference deleted
79. Reference deleted
80. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A SWOG trial. J Clin Oncol 19:3210-3218, 2001 (Pubitemid 32591438)
81. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
82. Quoix E, Zalcman G, Oster JP, et al: Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079-1088, 2011
83. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003 (Pubitemid 36395256)
84. Zukin M, Barrios CH, Pereira JR, et al: Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2. J Clin Oncol 31:2049-2053, 2013
85. Reference deleted
86. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000 (Pubitemid 30324363)
87. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
88. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
89. Reference deleted
90. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19:1336-1343, 2001 (Pubitemid 32202538)
91. von Plessen C, Bergman B, Andreson O, et al: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966-973, 2006 (Pubitemid 44606820)
92. Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007
93. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
94. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind phase 3 study. Lancet 374:1432-1440, 2009
95. Paz-Ares L: PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (abstr LBA 7507)
96. Barlesi F, Scherpereel A, Rittmeyer A, et al: Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004-3011, 2013
97. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small cell lung cancer: A multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
98. Behera M, Owonikoko TK, Chen Z, et al: Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. Lung Cancer 77:331-338, 2012
99. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
100. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 27:1227-1234, 2009
101. Dowlati A, Gray R, Sandler AB, et al: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:14-17-12, 2008
102. Mok T, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
103. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
104. Mitsudomi T, Morita S, Yatabe Y, et al: Efitibin versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label randomized phase 3 trial. Lancet Oncol 11:121-128, 2010
105. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre open-label randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
106. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
107. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
108. Gridelli C, Ciardiello F, Gallo C, et al: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 30:3002-3011, 2012
109. Ohashi K, Maruvka YE, Michor F, et al: Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31:1070-1080, 2013
110. Zhou W, Ercan D, Chen L, et al: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074, 2009
111. Camidge DR, Kono SA, Flacco A, et al: Optimizing the detection of lung cancer patients using anaplastic lymphoma kinase (ALK) gene rearrangements potientially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581-5590, 2010
112. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
113. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
114. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
115. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4/ALK. J Clin Oncol 27:4247-4253, 2009
116. Vansteenkiste J, Zielinski M, Linder A, et al: Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J Clin Oncol 31:2396-2403, 2013
117. Ulloa-Montoya F, Louahed J, Dizier B, et al: Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31:2388-2395, 2013
118. Butts C, Murray N, Maksymiuk A, et al: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674-6681, 2005 (Pubitemid 46190262)
119. Brahmer JR: Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31:1021-1028, 2013
120. Lynch TJ, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046-2054, 2012
121. Reference deleted
122. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
123. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD1) in melanoma. N Engl J Med 369:143-144, 2013
124. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
125. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013